Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Buprenorphine Induction in Fentanyl-Dependent Individuals
NCT04794790Phase 1Withdrawn
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- May 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of buprenorphine + naloxone in opioid use disorder (OUD), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Retention on Buprenorphine at 7 days. Planned start May 2022; status: withdrawn.
02
Drugs
buprenorphine + naloxone
03
Conditions
opioid use disorder (OUD)
Beyond the preview
Go deeper on NCT04794790.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04794790.